Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05641493 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | unknown | Phase 1 / Phase 2 | 49 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05802771 | Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice(LANTERN) | unknown | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER |
| 0 |
| Apr 7, 2023 |
| clinicaltrials |
| NCT05801107 | Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04840004 | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 2 | 24 | PlusVitech S.L.OTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05769504 | Examining Clinical Trial Participation for Small Cell Lung Cancer Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT04646837 | Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | unknown | Phase 1 / Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04974879 | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05555212 | To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation | unknown | Phase 1 | 72 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05785208 | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.(TEMPLE-2) | unknown | Phase 4 | 122 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02035683 | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy(PETRA) | unknown | N/A | 220 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03975114 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)(MILES-5) | unknown | Phase 2 | 460 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04992715 | PD-L1 Expression in Lung Cancer(PELICAN) | unknown | Phase 2 | 15 | NanoMab Technology (UK) LimitedINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05778045 | Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05620199 | Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy(UPLAN-I) | unknown | N/A | 20 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT04391283 | First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT04703153 | LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(LIQUIK) | unknown | — | 151 | Lucence Health Inc.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05127382 | Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer | unknown | — | 40 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04338620 | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | unknown | Phase 2 | 94 | Tang-Du HospitalOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05754736 | Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. | unknown | Phase 2 | 50 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05746598 | Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients | unknown | — | 178 | Ain Shams UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05741021 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 84 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05738317 | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | unknown | Phase 2 | 45 | Xiaorong DongOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737589 | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis | unknown | — | 50 | Xiaorong DongOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04153097 | Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | unknown | Phase 2 | 114 | Peking Union Medical College HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04996927 | 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC | unknown | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05257512 | Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 150 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05430386 | Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | unknown | Phase 1 | 174 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05533086 | PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer | unknown | — | 20 | Xiaohua ZhuOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 | clinicaltrials |
| NCT05425134 | Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer | unknown | — | 5,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05716672 | Impact of Lazertinib Dose Modification on Effectiveness and Safety | unknown | — | 200 | Pusan National University HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2023source: clinicaltrials